Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.
about
A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancerA systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC)Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer.Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents.The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR statusThird- and further-line therapy in advanced non-small-cell lung cancer patients: an overview.Prospect and progress of personalized peptide vaccinations for advanced cancers.Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature.
P2860
Q28487847-BD5567A3-A89F-4BEB-B4E8-3FA3F7312952Q34727967-D46469B3-DF59-4EA5-861D-BDB43B685B83Q35167535-26B844CC-B8C3-4763-A055-E2C1689EA582Q35429767-24F06C3F-B7AF-4A43-B87F-4D366A017CA1Q36765647-D6B0608E-5D0F-4BC4-AF16-02464A76B3CDQ37392573-DD333B13-9F2F-4535-9876-0634FEE48140Q38268170-CC09D7CF-B37A-4DDB-A332-E02AEA9C940CQ38758988-CE88ABF8-4CCB-4523-B0BB-568539D4CECBQ50238133-E9AA21DA-7157-4EA5-94DB-5440AA6FDF9E
P2860
Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Erlotinib or best supportive c ...... d cost-effectiveness analysis.
@en
Erlotinib or best supportive c ...... d cost-effectiveness analysis.
@nl
type
label
Erlotinib or best supportive c ...... d cost-effectiveness analysis.
@en
Erlotinib or best supportive c ...... d cost-effectiveness analysis.
@nl
prefLabel
Erlotinib or best supportive c ...... d cost-effectiveness analysis.
@en
Erlotinib or best supportive c ...... d cost-effectiveness analysis.
@nl
P2093
P1433
P1476
Erlotinib or best supportive c ...... d cost-effectiveness analysis.
@en
P2093
Barbara Melosky
Ian Cromwell
Kimberly van der Hoek
Suzanne C Malfair Taylor
P304
P356
10.1016/J.LUNGCAN.2011.12.003
P577
2012-01-09T00:00:00Z